The preventive effects of dexmedetomidine against intestinal ischemia-reperfusion injury in Wistar rats

Xue-kang Zhang 1*, Xiao-ping Zhou 2, Qin Zhang 1, Feng Zhu 3

1 Department of Anesthesiology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China
2 Grade 2012 of Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi 330006, China
3 Intensive Care Unit (ICU), First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China

ARTICLE INFO

Article type: Original article

Article history:
Received: Sep 13, 2014
Accepted: May 19, 2015

Keywords:
Dexmedetomidine
Inflammatory response
Intestinal injury
Ischemia-reperfusion

ABSTRACT

Objective(s): Intestinal ischemia-reperfusion is a major problem, which may lead to multiorgan failure and death. The aim of this study was to evaluate the protective effects of dexmedetomidine on cell proliferation, antioxidant system, cell death, and structural integrity in intestinal injury induced by ischemia-reperfusion in rats.

Materials and Methods: Animals were randomized into three groups: group A, sham-operated or control; group B, intestinal ischemia/reperfusion (IR); and group C, intestinal IR pretreated with 50 μg of dexmedetomidine. Intestine tissue was collected from all rats 30 min after desufflation, and fresh frozen for histological and biochemical evaluation.

Results: The intestinal tissue of group B rats showed a significant decrease in the antioxidant enzyme activities. However, these enzyme activities were improved by the administration of dexmedetomidine. Inhibiting the protein expression of MCP7, PAR2, P-JAK, P-STAT1, and P-STAT3 enzyme activities. However, these enzyme activities were improved by the administration of dexmedetomidine. Inhibiting the protein expression of MCP7, PAR2, P-JAK, P-STAT1, and P-STAT3

Conclusions: Intraperitoneal injection of dexmedetomidine significantly protected intestine IR injury in rats by inhibiting the inflammatory response, intestinal epithelial apoptosis, and maintaining structural integrity of intestinal cells.

Introduction

The condition by which the deprivation of blood flow leads to insufficient oxygen and nutrient supply to the tissue is called ischemia. Reperfusion injury refers to the tissue damage inflicted when blood flow is restored after an ischemic period for a minimum of 10 min. The intestinal ischemia/reperfusion (IR) injury causes damage to the intestinal mucosa, serious impairment of the local microvasculature, increased vascular and mucosal permeability, and multiple organ failure (1). Emerging studies have observed increased cell death or tissue damage during IR of the gut that plays a vital role in the pathogenesis of IR induced intestinal injury. The intestinal IR model has often been practiced as an experimental model to study apoptosis or to investigate reactive oxygen species induced oxidative stress especially during reperfusion in small intestine (2-4). However, a specific treatment for IR is not in practice. Several antioxidants and antibodies against adhesion molecules have shown to be protective against IR injury (3, 5).

Contemporary researches suggest the tissue protective effect of dexmedetomidine by reducing cerebral, cardiac, intestinal, and renal injury (6-8). The highly selective and potent α2-adrenergic agonist dexmedetomidine is an effective sedative, anxiolytic, and analgesic agent used in postoperative patients as mechanical ventilation (9, 10). Previous studies have suggested that mast cells are critical regulators of physiological function of the intestine and participate in the inflammatory pathogenic process of IR (11, 12). Histamine and tryptase can trigger inflammation and cause tissue injury by increasing the mucosal membrane permeability and promoting inflammatory factor production.

Mast cells protease 7 (MCP7) is the primary subtype of tryptase synthesized by immature mast cells. Protease-activated receptor 2 (PAR2) can be activated by tryptase and modulate inflammatory response (13). The Janus kinase/signal transducer and activator of the transcription (JAK/STAT)
signaling pathway play a vital role in transducing signals for various cytokines and growth factors (14). After a cascade of intracellular phosphorylation events, they dimerize and translocate to the nucleus, modulate the transcription of many target genes, and thereby stimulate cell proliferation, differentiation, cell migration and apoptosis, and other processes (15). Based on the protective effect of dexmedetomidine on various tissues, the present study aimed to investigate the effects of dexmedetomidine on intestinal injury induced by IR in rats.

Materials and Methods

Animals and experimental groups

Male Wistar rats with almost similar body weight (208.62 to 212.87 g) were taken for the experiment. Animals were randomly assigned into 3 groups including group A (sham-operated or control, n=8); group B (intestinal IR, n=8); and group C (pretreated intestinal IR, n=8, and 50 μg of dexmedetomidine was intraperitoneally injected 30 min before intestinal IR); the dosage was determined from previous study (16). The animals were housed in a temperature controlled room with 12 hr light–dark cycles, and were fed with regular rat chow and water ad libitum, but were fasted overnight prior to the experiments. All experiments described herein were conducted with the approval of the Institutional Animal Care and Use Committee of First Affiliated Hospital of Nanchang University, Jiangxi, China.

Intestinal ischemia/reperfusion injury

The animals were anesthetized using the combination of sodium pentobarbital (390 mg) and sodium phenytoin (50 mg/ml), and a midline abdominal incision was made. The superior mesenteric artery (SMA) was identified and freed by blunt dissection. A microvascular clamp was placed at the root of SMA to cause complete arrest of blood flow for 60 min, and the clamp was loosened to form reperfusion injury (17). At the end of the experiment, the animals were sacrificed by administering over dose of anesthesia. No analgesics, antibiotics, or euthanasia agents were used. The blood samples and intestinal tissue biopsies were taken. The tissues were fresh frozen for histological and biochemical evaluation. As this is a preliminary study to reveal the protective effect of dexmedetomidine, this study doesn't pursue further with the survival.

Determination of antioxidant enzyme activity

The innate antioxidant enzymes catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (Gpx) were analyzed. To calculate the specific enzyme activity, protein concentration in each sample was estimated by the method of Bradford (18). CAT activity was assayed in hemolysates of erythrocytes by monitoring the consumption of H2O2 at 240 nm, as described by Aebi (19). The SOD activity was determined according to the method of Sun et al (20). One unit of SOD was defined as the amount of enzyme causing 50% inhibition in the nitroblue tetrazolium reduction rate. The activity of SOD was termed as units per milligram protein. The activity of Gp was determined essentially as described by Rotruck et al (21). In the test, the enzyme activity was expressed as units/mg protein (one unit was the amount of enzyme that converted 1 μmol of GSH to the oxidized form of glutathione (GSSH) in the presence of H2O2/min).

Western blot analysis

The protein lysates were prepared from frozen tissues in ice-cold RIPA buffer (Sigma-Aldrich). The extracted protein was separated in a 10% sodium dodecyl sulfate (SDS)-PAGE and then electrophoretically transferred to a nitrocellulose membrane (Hybond, Amersham Biosciences, Little Chalfont, UK). Membranes were blocked with 5% nonfat milk powder in TBS for 1 hr at room temperature. These membranes were subjected to immunoblot analysis with antibodies to MCP7, PAR2, P-JAK2, P-STAT1, and P-STAT3. The protein-antibody immune complexes were detected with horseradish peroxidase conjugated secondary antibodies and enhanced chemiluminescence reagents (Pierce Biotechnology, Rockford, IL). β‐actin was used as an internal control for protein normalization, and values were compared with those of group A.

Histology and immunohistochemical staining

Paraformaldehyde fixed, paraffin embedded samples of small intestine or jejunum were also cut 5 mm in thickness, deparaffinized in xylene, rehydrated in graded ethanol, and then were stained with haematoxylin-eosin (HE) for histological observation under light microscope (Olympus, Japan) and photographed. Immunohistochemical staining for active caspase-3 was performed using the streptavidin-biotin-peroxidase method. For negative control, phosphate-buffered saline was used instead of antibody. Cytoplasm with dark red staining was assessed as positive. The proliferating cells in intestine sections were detected by proliferating cell nuclear antigen (PCNA) immunohistochemistry.

Statistical analysis

Data were analyzed by statistical software (SPSS Inc, Chicago, IL). All values are given as mean±standard error of the mean. P<0.05 was considered as statistical significance.

Results

Dexmedetomidine improved antioxidant enzyme activity

The level of antioxidant enzymes (CAT, SOD, and Gpx) activity was determined using the rat intestinal tissues from all three experimental groups. The activity
levels were compared between groups. The enzymes CAT, SOD, and GpPx levels in the intestinal I/R (group B) were lower in comparison with sham (group A) and pretreated intestinal I/R (group C). However, the levels of these enzymes were significantly (P<0.05) lower in I/R+ dexmedetomidine group compared to the sham group (Figure 1).

**Dexmedetomidine inhibited inflammatory protein expressions**

The Western blotting analysis was performed to demonstrate the effect of dexmedetomidine on inflammatory proteins. The MCP7 and PAR2 protein levels were significantly elevated in intestinal I/R group. However, these elevated protein levels were not seen in dexmedetomidine administered intestinal I/R rats (Figure 2). Similarly, dexmedetomidine administration controlled the JAK/STATs pathway by inhibiting the protein phosphorylation of JAK, STAT1, and STAT3. The protein level of Sham group was used as control. These results confirm that dexmedetomidine inhibits the mast cell proteins and JAK/STAT pathway on intestinal I/R injury (Figure 2).

**Dexmedetomidine protects structural integrity from intestinal I/R Injury**

To examine the protective effect of dexmedetomidine against I/R injury in small intestinal, we implemented histopathology and immunohistochemical staining methods in the jejunal tissues of experimental groups’ rats. The normal histological structure was observed in HE stained sections of sham group rats (Figure 3A). Severe disruption of structural integrity in brush border, including loss of mucus, villi, and wide spread necrotic area was observed in I/R injured rats (Figure 3B). However, these damages were protected in dexmedetomidine-administered I/R rats (Figure 3C). In immunohistochemical staining we observed an
Dexmedetomidine against intestinal ischemia-reperfusion

Zhang et al

Iran J Basic Med Sci, Vol. 18, No. 6, Jun 2015

Figure 4. Represents the caspase-3 staining for immunoreactive cells in rat jejunal tissue. (A) No immunoreactive cells appeared in sham-operated control rats; (B) rats subjected to I/R injury exhibited more number of active caspase-3 immunoreactive cells (arrow indicated); (C) dexmedetomidine administered intestinal I/R rats show very less immunoreactive cells. Scale bar = 50 µm

intense staining for active caspase-3 in the cytoplasm of epithelial cells of rats subjected to I/R injury (group B). However very few caspase-3 immunoreactive cells were observed in dexmedetomidine administered I/R group and no caspase-3 stain was observed in sham group (Figure 4). The PCNA immunoreactivity staining clearly showed a significant decrease or no PCNA positive crypt cells in intestinal I/R rats. However, increased cell proliferations intensity and number of PCNA-positive crypt cells similar to that of sham group were observed in dexmedetomidine pretreated I/R rats (Figure 5). These results again proved the tissue protective effect of dexmedetomidine against intestinal I/R injury.

Discussion

In this study, we demonstrated the protective effect of dexmedetomidine against the intestinal injury induced by I/R using rat model. Similar study demonstrated the effect of using testosterone however the mechanistic role was unclear (22). In the present study, the investigation was focused on the role of dexmedetomidine on cell proliferation, differentiation, cell migration, and other processes. The intestinal I/R injury is a complex, multifactorial, and pathophysiological process that involves the dysfunction of absorption, bacterial translocation, production of reactive oxygen species, cytokines, nitric oxide, and initiates multiorgan dysfunction syndrome (23, 24). Intestinal mucosal mast cells are particularly frequent in close proximity to epithelial surfaces, where they are strategically located for optimal interaction with the environment and for their putative functions of host defense (25). The antioxidant enzymes (CAT, SOD, and Gpx) assist cells in repairing damaged membranes against oxidative damage. In the present study, a significant increase in CAT, SOD, and Gpx activities was observed in dexmedetomidine-administered intestinal I/R group. These results indicate that dexmedetomidine has potent free radical scavenging and antioxidant properties during the progress of I/R injury. Our results are consistent to the previous study that dexmedetomidine infusion (10), L-carnitine (26) and resveratrol (27) prevent the production of reactive oxygen species during mesenteric I/R injury in rats.

Figure 5. Represents the PCNA staining for immunoreactive cells in crypts of the jejunum. (A) sham-operated control rats; (B) rats subjected to I/R injury; (C) dexmedetomidine administered intestinal I/R rats. Scale bar = 100 µm
Activated mast cells participate in the pathogenesis of I/R related inflammation and intestinal injury (28). To understand the mechanisms underlying the therapeutic effect of dexmedetomidine, we detected the relative levels of MCP-1 in the intestinal tissues from all groups and observed a significantly lower level in treatment group than that of intestinal I/R groups of rat. Furthermore, the relative levels of PAR2 in the intestinal tissues from the treatment group of rats were significantly lower than those in the intestinal I/R group. Our data were consistent with the report that treatment with anti-PAR2 mitigates I/R related inflammation and reduces the levels of TNF-α (29). Next we investigated the relationship between JAK2 associated signaling cascades and intestinal I/R triggered intestinal injury. Other than sham group, phosphorylations of JAK2, STAT3, and STAT5, reflecting activation, were significantly potentiated after reperfusion. This shows that JAK/STAT pathway was dramatically activated under intestinal I/R condition. In the present study, we documented that treatment with dexmedetomidine significantly down regulates the phosphorylation of JAK2 and its downstream molecules STAT3/STAT5, which is consistent with the study of Yang et al (30).

The current study evaluated the role of dexmedetomidine on intestinal architecture and apoptosis in small intestinal I/R injury and determined its protective and antiapoptotic effects against intestinal injury. In the present study, the histopathology showed a significant protective effect of dexmedetomidine against intestinal I/R injury. This is consistent with recent report showed dexmedetomidine reduces systemic levels of interleukin-6, tumor necrosis factor-α, and high mobility group box 1 following lipo-polysaccharide infusion or sepsis in animals; indicating its anti-inflammatory effects against renal I/R injury (6). Previous studies have shown that erythropoietin has protective effects against I/R injury in several tissues (31). In addition, dexmedetomidine was known to alter the cardiovascular response during infrarenal aortic crossclamping in sevoflurane anesthetized dogs (32, 33). Similarly, our experiment showed that apoptotic index of caspase-3, as a key caspase involved in the apoptotic pathway in the intestinal mucosa, was markedly reduced in dexmedetomidine pretreated group, which also promotes the cell proliferating index in PCNA staining. Homeostasis of epithelial architecture in the small intestine is regulated by both cell proliferation and cell death or apoptosis (34). Since intestinal epithelial cells have short proliferation cycle and powerful growth ability, regeneration in the intestinal tissue is quite fast. Another factor, which could damage the integrity of the intestinal mucosal barrier, is the inhibition of epithelial cell proliferation (35). Thus dexmedetomidine has been demonstrated as a potent agent for the protection of intestinal I/R injury. The clinical implication of our study represent that “dexmedetomidine” in spite of an effective sedative agent, shows the ability to prevent I/R induced intestinal injury based on its protective effect on cell proliferation, antioxidant system, cell death, and structural integrity.

Conclusion
Our studies showed that dexmedetomidine protects intestine against I/R injury, at least in part, increasing the antioxidant enzyme activity, cell proliferation, and inhibitory effects on injury induced activation of caspase-3, MCP-1, PAR2 protein level, JAK/STAT signaling pathway. On extrapolating our data to clinical setting, dexmedetomidine may serve as a clinical strategy to prevent intestinal I/R injury.

Acknowledgment
The authors thank Dr Xue-Kang Zhang of the Department of Anesthesiology, First Affiliated Hospital of Nanchang University (Nanchang, China) for providing the Western blot analysis, Histology and immunohistochemical staining.

References
1. Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the ‘motor’ of critical illness. Shock 2007; 28:384-393.
2. Noda T, Iwaläri R, Fujimoto K, Matsuo S, Aw TY. Programmed cell death induced by ischemia-reperfusion in rat intestinal mucosa. Am J Physiol 1998; 274:270-276.
3. Kacmaz M, Ozturk HS, Karaayvaz M, Güven C, Durak I. Enzymatic antioxidant defence mechanism in rat intestinal tissues changed after ischemia-reperfusion. Effects of an allopurinol plus antioxidant combination. Can J Surg 1999; 42:427-431.
4. Fujise T, Iwakiri R, Amemori S, Kakimoto T, Yokoyama F, Salata Y, et al. Apoptotic pathway in the rat small intestinal mucosa is different between fasting and ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2006; 291:G110–116.
5. Kazez A, Demirbag M, Üstündag B, Ozercan IH, Sağlam M. The role of melatonin in prevention of intestinal ischemia-reperfusion injury in rats. J Pediatr Surg 2000; 35:1444-1448.
6. Gu J, Sun P, Zhao H, Watts HR, Sanders RD, Terrando N, et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care 2011; 15:R153.
7. Yoshitomi O, Cho S, Hara T, Shibata I, Maekawa T, Ureshino H, et al. Direct protective effects of dexmedetomidine against myocardial ischemia reperfusion injury in anesthetized pigs. Shock 2012; 38:92-97.
8. Zhang XY, Liu ZM, Wen SH, Li YS, Li Y, Yao X, et al. Dexmedetomidine administration before, but not after, ischemia attenuates intestinal injury induced by intestinal ischemia-reperfusion in rats. Anesthesiology 2012; 116:1035-1046.
9. Paris A, Tonner P. Dexmedetomidine in anaesthesia. Curr Opin Anesthesiol 2005; 18: 412-418.
10. Ind F, Dogan IV, Eti Z, Deniz M, Gogus Y. The effects of dexmedetomidine infusion on the formation of reactive oxygen species during mesenteric ischemia-reperfusion injury in rats. Marmara Med J 2007; 20: 154-160.
11. Andoh A, Fujiyama Y, Araki Y, Kimura T, Tsujikawa T, Bamba T. Role of complement activation and mast cell degranulation in the pathogenesis of rapid intestinal ischemia/reperfusion injury in rats. Digestion 2001; 63:103-107.
12. Bischoff SC. Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 2009; 31:185.
13. Shin K, Nigrovic PA, Crish J, Boilard E, McNeil HP, Larabee KS, et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009; 182:647.
14. Oshea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109:S121YS131.
15. Schindler C, Strehlow I. Cytokines and STAT signaling. Adv Pharmacol 2008; 47:113Y174.
16. Si Y, Bao H, Han L, Shi H, Zhang Y, Xu L, et al. Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation. J Transl Med 2013; 11:141.
17. Fu XB, Sheng ZY, Wang YP, Wang Y, Ye Y, Xu M, et al. Basic fibroblast growth factor reduces the gut and liver morphologic and functional injuries after ischemia and reperfusion. J Trauma 1997; 42:1080-1085.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
19. Aebi H. Catalase in vitro. Meth Enzymol 1984; 105: 121-126.
20. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem1988; 34: 497-500.
21. Rottruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973; 79:588-590.
22. Albayrak Y, Halici Z, Odabasoglu F, Unal D, Keles ON, Malkoc I, et al. The effects of testosteron on intestinal ischemia/reperfusion in rats. J Invest Surg 2011; 24:283-291.
23. Carden DL, Granger DN. Pathophysiology of ischaemiareperfusion injury. J Pathol 2000; 190:255-266.
24. Antonsson JB, Fiddian-Green RG. The role of the gut in shock and multiple system organ failure. Eur J Surg 1991; 157:3-12.
25. Penissi AB, Rudolph MI, Piezzi RS. Role of mast cells in gastrointestinal mucosal defense. Biocell 2003; 27:163-172.
26. Yuan Y, Guo H, Zhang Y, Zhou D, Gan P, Liang DM, et al. Protective effects of L-carnitine on intestinal ischemia/reperfusion injury in a rat model. J Clin Med Res 2011; 3:78-84.
27. Dong W, Li F, Pan Z, Liu S, Yu H, Wang X, et al. Resveratrol ameliorates subacute intestinal ischemia-reperfusion injury. J Surg Res 2013; 185:182-189.
28. Boros M, Ordogh B, Kaszaki J, Nagy S. The role of mast cell degranulation in ischaemia-reperfusion-induced mucosal injury in the small intestine. Ann Acad Med Singapore 1999; 28:79-84.
29. Yoshida N, Takagi T, Isozaki Y, Suzuki T, Ichikawa H, Yoshikawa T. Proinflammatory role of protease-activated receptor-2 in intestinal ischemia/reperfusion injury in rats. Mol Med Rep 2011; 4: 81-86.
30. Yang N, Luo M, Li R, Huang Y, Zhang R, Wu Q, et al. Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rat. Nephrol Dial Transplant 2008; 23:91Y100.
31. Guneli E, Cavidar Z, Islekel H, Sarioglu S, Erbayraktar S, Kiray M, et al. Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats. Mol Med 2007; 13:509-517.
32. da Silva AL, Kinsky MP. Dexmedetomidine alters the cardiovascular response during infra-renal aortic cross-clamping in sevoflurane-anesthetized dogs. J Invest Surg 2008; 21:360-368.
33. Braz LG, Braz JR, Castiglia YM, Vianna PT, Vane LA, Módolo NS, et al. Dexmedetomidine alters the cardiovascular response during infra-renal aortic cross-clamping in sevoflurane-anesthetized dogs. J Invest Surg 2008; 21:360-368.
34. Potten CS, Booth C. The role of radiation-induced and spontaneous apoptosis in the homeostasis of the gastrointestinal epithelium: a brief review. Comp Biochem Physiol B Biochem Mol Biol 1997; 118:73-78.
35. Xu LF, Li J, Sun M, Sun HW. Expression of intestinal trefoil factor, proliferating cell nuclear antigen and histological changes in intestine of rats after intrauterine asphyxia. World J Gastroenterol 2005; 11:2291-2295.